Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

BACKGROUND: Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily metabolized by uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A1, a known polymorphic enzyme with functional variants that can af...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Parul, Xue, Zhengyu, King, Karen S, Parham, Laura, Ford, Susan, Lou, Yu, Bakshi, Kalpana K, Sutton, Kenneth, Margolis, David, Hughes, Arlene R, Spreen, William R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366207/
https://www.ncbi.nlm.nih.gov/pubmed/32361755
http://dx.doi.org/10.1093/jac/dkaa147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366207/
https://www.ncbi.nlm.nih.gov/pubmed/32361755
http://dx.doi.org/10.1093/jac/dkaa147

Ejemplares similares